OSE Immunotherapeutics climbed 8% on Monday on the Paris Bourse following the publication of preclinical results in acute lymphoblastic leukemia (ALL) in the scientific journal 'Blood'.

The abstract reports that the IL-7R immunotherapy Lusvertikimab developed by OSE showed 'significant' in vivo efficacy in preclinical models derived from samples of this childhood cancer.

These preclinical data come from a collaborative research program conducted by OSE Immunotherapeutics and the Schleswig-Holstein University Medical Center in Kiel (Germany).

According to the authors, Lusvertikimab could represent a promising new option for immunotherapy, or even for significantly improving the treatment of refractory or relapsed ALL.

Treatment options remain very limited for this disease today, hence the urgent medical need for innovative therapeutic approaches.

Lusvertikimab targets ALL cells through a dual mode of action: on the one hand, by blocking the proliferative signals induced by interleukin-7, and on the other, by causing macrophages to eliminate leukemia cells.

Copyright (c) 2024 CercleFinance.com. All rights reserved.